, Tracking Stock Market Picks
Enter Symbol:

Mkt Outperform
up 93.66 %

MEDIVATION INC (MDVN) rated Mkt Outperform by JMP Securities

Posted on: Thursday,  Mar 28, 2013  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform MEDIVATION INC (NASDAQ: MDVN) on 03/28/2013, when the stock price was $47.54.
Since then, MEDIVATION INC has gained 93.67% as of 01/27/2016's recent price of $92.07.
If you would have followed this JMP Securities's recommendation on MDVN, you would have gained 93.66% of your investment in 1035 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/28/2013 8:25 AM Buy
as of 12/13/2013
1 Week up  1.51 %
1 Month up  0.57 %
3 Months up  5.69 %
1 YTD up  32.81 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy